The aim of the present study was to test the effect of CYP2C19 metabolic phenotypes when antidepressants metabolized by CYP2C19 (citalopram, escitalopram, sertraline, amitriptyline, and clomipramine) are used by patients with bipolar disorder. This evidence concerns the gene CYP2C19 and bipolar disorder.